Refractory Cancer Clinical Trial
Official title:
Individualized Treatments in Adults With Relapsed/Refractory Cancers
A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.
Treatment itself will not be given as part of this trial. The results of the drug sensitivity test (DST) and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide the most appropriate treatment for each case, with the option to add one or more personalized (assay-guided) drug(s) from the investigational platform. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03336931 -
PRecISion Medicine for Children With Cancer
|
||
| Completed |
NCT00530192 -
Molecular Profiling Protocol (SCRI-CA-001)
|
Phase 0 | |
| Recruiting |
NCT05852717 -
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06229340 -
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
|
Phase 2 | |
| Completed |
NCT00551850 -
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
|
Phase 1 | |
| Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
| Terminated |
NCT04092179 -
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06184035 -
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Recruiting |
NCT05864144 -
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03187288 -
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
|
Phase 1 | |
| Terminated |
NCT01320280 -
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03441100 -
TCR-engineered T Cells in Solid Tumors: IMA202-101
|
Phase 1 | |
| Recruiting |
NCT05359445 -
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03686124 -
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04337580 -
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04310345 -
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
|
N/A | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06208657 -
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05662397 -
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
|
Phase 1/Phase 2 |